Charles River Laboratories International, Inc. $CRL Shares Sold by UNIVEST FINANCIAL Corp

UNIVEST FINANCIAL Corp trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 92.3% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 2,652 shares of the medical research company’s stock after selling 31,595 shares during the period. UNIVEST FINANCIAL Corp’s holdings in Charles River Laboratories International were worth $402,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CRL. GAMMA Investing LLC raised its position in Charles River Laboratories International by 61.6% in the first quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company’s stock valued at $210,000 after purchasing an additional 533 shares during the period. Cambridge Investment Research Advisors Inc. raised its position in Charles River Laboratories International by 6.8% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,926 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 123 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Charles River Laboratories International by 15.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company’s stock valued at $952,000 after purchasing an additional 817 shares during the period. Mather Group LLC. lifted its holdings in shares of Charles River Laboratories International by 86.3% in the 1st quarter. Mather Group LLC. now owns 667 shares of the medical research company’s stock worth $100,000 after acquiring an additional 309 shares during the last quarter. Finally, Vontobel Holding Ltd. lifted its holdings in shares of Charles River Laboratories International by 149.4% in the 1st quarter. Vontobel Holding Ltd. now owns 4,531 shares of the medical research company’s stock worth $682,000 after acquiring an additional 2,714 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 0.6%

Shares of NYSE:CRL opened at $179.08 on Friday. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $230.02. The company’s 50 day moving average is $166.68 and its two-hundred day moving average is $152.14. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a market cap of $8.81 billion, a PE ratio of -134.65, a P/E/G ratio of 4.83 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. During the same period in the prior year, the firm posted $2.80 EPS. The company’s quarterly revenue was up .6% compared to the same quarter last year. Equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on CRL. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and upped their price objective for the stock from $142.00 to $195.00 in a report on Tuesday, September 9th. Barclays upgraded shares of Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $165.00 to $195.00 in a report on Thursday, October 2nd. JPMorgan Chase & Co. upped their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. William Blair upgraded shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Finally, Wall Street Zen lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 23rd. Eight analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $181.29.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 800 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the transaction, the executive vice president directly owned 24,116 shares of the company’s stock, valued at $3,800,681.60. This trade represents a 3.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).